Hemophilia is a rare blood disorder in which blood doesn’t clot normally because of a lack of clotting factor, a blood protein. Individuals with hemophilia don’t bleed any faster than others, but they often bleed for a longer amount of time.
Hemophilia doesn’t occur very often, and about one in every 10,000 people are born with the disease. There are two types, hemophilia A and hemophilia B, that each refer to the lack of a different type of clotting factor. But the disease often presents the same way in people with either type of hemophilia.
In the vast majority of cases, hemophilia is a hereditary disease that is passed down from parents to children. In very rare instances, it can be acquired at some point during your lifetime. When the average person begins bleeding, the platelets in the blood start to stick together with the help of clotting factor to plug the hole and stop the bleeding. But individuals with hemophilia have little or no clotting factor, so the bleeding continues even after it should stop. This can range from mild to severe in nature, and hemophilia can be quite dangerous if left untreated.
The primary treatment for hemophilia is known as replacement therapy. Essentially, this is a therapy administered by an IV or injection that replaces the missing clotting factor in the body with new clotting factor. This can be done periodically as a preventive measure, or only periodically as the individual needs it.
There are other treatments for hemophilia, as well. For example, certain hormonal therapies can release stores of clotting factor that are already in the body, and there are also drugs often given along with replacement therapy that help prevent blood clots from breaking down.
SOURCES: World Federation of Hemophilia; National Institutes of Health: National Heart, Lung, and Blood Institute.
'Therapeutic skin grafts' might someday treat multiple diseases, researchers say
Currently, genetic bleeding disorder is treated with injections
Small, preliminary trial suggests it may free hemophilia B patients from transfusions
One pinpoints when standard therapy works best, while the other uncovers the promise of a new drug
Researchers surprised by shortcomings in treatment of men with severe forms of the blood-clotting disorder
California-based study finds drugs for the blood disorder take up large share of budget
The bleeding disorder affects both males and females
And fewer episodes of bleeding
Alprolix requires less frequent injections
Rare condition could be life threatening
First of its kind remedy
Non-contact activities safest, allowing children to enjoy exercise, experts say
Severity of the bleeding condition was reduced for men with type B disorder, study finds
For some patients, using medicine to stave off, not just treat bleeds, could decrease joint damage
Stanford researchers question use of expensive drug for other medical treatments despite risk
Made from donated plasma
The blood disorder can lead to additional problems
Those without blood disorder who were given it were twice as likely to have trouble, review found
Successful blood-clotting in lab could pave way for human trials, researchers say
Hemophilia A affects about 15,000 in the U.S.
Xyntha supplements affected blood factor
Experiments in mice may lead to new treatments for the disease, study suggests
Protect yourself from injury
Finding could lead to new treatment for diseases like hemophilia, study says
Mothers of hemophiliacs have lower death rate
Eliminates possible germ transmission
New test quickly measures thrombin in blood
But there's disagreement over determining correct dosage
Technique shows promise in lab mice
British boy is namesake for hemophilia B
Altered cells may correct genetic flaw